By Sam Boughedda
Investing.com -- Shares of telehealth company GoodRx Holdings, Inc. (NASDAQ:GDRX) are down Tuesday morning after the company reported earnings after the close Monday, missing revenue and earnings per share estimates.
The company missed earnings per share estimates by 1 cent, coming in at $0.09, with revenue rising 39% to $213.26. Analysts polled by Investing.com anticipated EPS of $0.10 on revenue of $217.46 million.
The company said it sees first quarter revenue at approximately $200 million, coming in below consensus, while full-year 2022 growth is seen around 23%.
"We see significant opportunities to build on our 2021 growth and success to deliver a very strong 2022, reaching more consumers and providers and bringing more value to each stage of the healthcare journey," GoodRx told investors.
However, those guidance numbers disappointed analysts and investors alike, with GoodRx shares plunging more than 38% to a record low.
Analysts at Cowen and Credit Suisse downgraded the stock while several others lowered their price targets. Most pointed to 2022 guidance as to the reason for their re-ratings.